Search Results - "Jacobs, Graeme Brendon"

Refine Results
  1. 1

    Mutations in HIV-1 gag and pol Compensate for the Loss of Viral Fitness Caused by a Highly Mutated Protease by Kozísek, Milan, Henke, Sandra, Sasková, Klára Grantz, Jacobs, Graeme Brendon, Schuch, Anita, Buchholz, Bernd, Müller, Viktor, Kräusslich, Hans-Georg, Rezácová, Pavlína, Konvalinka, Jan, Bodem, Jochen

    Published in Antimicrobial Agents and Chemotherapy (01-08-2012)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  2. 2

    Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding by Chitongo, Rumbidzai, Obasa, Adetayo Emmanuel, Mikasi, Sello Given, Jacobs, Graeme Brendon, Cloete, Ruben

    Published in PloS one (07-05-2020)
    “…Resistance associated mutations (RAMs) threaten the long-term success of combination antiretroviral therapy (cART) outcomes for HIV-1 treatment. HIV-1…”
    Get full text
    Journal Article
  3. 3

    Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations by Mikasi, Sello Given, Isaacs, Darren, Chitongo, Rumbidzai, Ikomey, George Mondide, Jacobs, Graeme Brendon, Cloete, Ruben

    Published in BMC infectious diseases (23-04-2021)
    “…The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa by Obasa, Adetayo Emmanuel, Mikasi, Sello Given, Brado, Dominik, Cloete, Ruben, Singh, Kamlendra, Neogi, Ujjwal, Jacobs, Graeme Brendon

    Published in Frontiers in microbiology (20-03-2020)
    “…The South African national combination antiretroviral therapy (cART) roll-out program started in 2006, with over 4.4 million people accessing treatment since…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa by Obasa, Adetayo Emmanuel, Ambikan, Anoop T, Gupta, Soham, Neogi, Ujjwal, Jacobs, Graeme Brendon

    Published in BMC infectious diseases (25-02-2021)
    “…HIV-1C has been shown to have a greater risk of virological failure and reduced susceptibility towards boosted protease inhibitors (bPIs), a component of…”
    Get full text
    Journal Article
  8. 8

    Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors by Isaacs, Darren, Mikasi, Sello Given, Obasa, Adetayo Emmanuel, Ikomey, George Mondinde, Shityakov, Sergey, Cloete, Ruben, Jacobs, Graeme Brendon

    Published in Viruses (26-08-2020)
    “…The process of viral integration into the host genome is an essential step of the HIV-1 life cycle. The viral integrase (IN) enzyme catalyzes integration. IN…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12

    HIV-1 subtypes B and C unique recombinant forms (URFs) and transmitted drug resistance identified in the Western Cape Province, South Africa by Jacobs, Graeme Brendon, Wilkinson, Eduan, Isaacs, Shahieda, Spies, Georgina, de Oliveira, Tulio, Seedat, Soraya, Engelbrecht, Susan

    Published in PloS one (07-03-2014)
    “…South Africa has the largest worldwide HIV/AIDS population with 5.6 million people infected and at least 2 million people on antiretroviral therapy. The…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Near full-length HIV-1 subtype B sequences from the early South African epidemic, detecting a BD unique recombinant form (URF) from a sample in 1985 by Obasa, Adetayo Emmanuel, Engelbrecht, Susan, Jacobs, Graeme Brendon

    Published in Scientific reports (17-04-2019)
    “…HIV-1 subtype C is the most prevalent subtype in South Africa. Although subtype B was previously detected in South Africa, there is limited sequence…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa by Brado, Dominik, Obasa, Adetayo Emmanuel, Ikomey, George Mondinde, Cloete, Ruben, Singh, Kamalendra, Engelbrecht, Susan, Neogi, Ujjwal, Jacobs, Graeme Brendon

    Published in Scientific reports (16-03-2018)
    “…HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to characterize the HIV-1 IN gene in a South African context…”
    Get full text
    Journal Article
  17. 17

    Peripheral blood lymphocyte proviral DNA predicts neurocognitive impairment in clade C HIV by Ruhanya, Vurayai, Jacobs, Graeme Brendon, Nyandoro, George, Paul, Robert H., Joska, John A., Seedat, Soraya, Glashoff, Richard Helmuth, Engelbrecht, Susan

    Published in Journal of neurovirology (01-12-2020)
    “…It is not known if proviral DNA in the periphery corresponds to cognitive status in clade C as it does in clade B and recombinant forms. A cross-sectional…”
    Get full text
    Journal Article
  18. 18

    HIV-1 subtype C Tat exon-1 amino acid residue 24K is a signature for neurocognitive impairment by Ruhanya, Vurayai, Jacobs, Graeme Brendon, Paul, Robert H., Joska, John A., Seedat, Soraya, Nyandoro, George, Glashoff, Richard H., Engelbrecht, Susan

    Published in Journal of neurovirology (01-06-2022)
    “…Variation and differential selection pressures on Tat genes have been shown to alter the biological function of the protein, resulting in pathological…”
    Get full text
    Journal Article
  19. 19

    Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa by Brado, Dominik, Obasa, Adetayo Emmanuel, Ikomey, George Mondinde, Cloete, Ruben, Singh, Kamalendra, Engelbrecht, Susan, Neogi, Ujjwal, Jacobs, Graeme Brendon

    Published in Scientific reports (16-03-2018)
    “…HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to characterize the HIV-1 IN gene in a South African context…”
    Get full text
    Journal Article
  20. 20